Lentivirus-mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery

Cellular Physiology and Biochemistry

Volumn 26, Issue 3, 2010, Pages 441-448

  Yang, Jian ^a   Jiang, Hong ^a   Chen, Si Si ^a   Chen, Jing ^a   Li, Wan Qiang ^a   Xu, Sheng Kai ^a   Wang, Ji Chun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Endothelial regrowth; Gene therapy; Lentivirus; Neointimal formation

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALLOON CATHETER; BLOOD VESSEL COMPLIANCE; CAROTID ARTERY INJURY; CATHETER COMPLICATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; INTIMA; LENTIVIRINAE; MORPHOMETRICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RESTENOSIS; WESTERN BLOTTING;

LENTIVIRUS; RATTUS;

EID: 78650000249     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320567     Document Type: Article

References (45)

1. Grüntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;30:61-68.
2. Kobayashi J: Current status of coronary artery bypass grafting. Gen Thorac Cardiovasc Surg 2008;56:260-267.
3. Bermejo J, Botas J, García E, Elízaga J, Osende J, Soriano J, Abeytua M, Delcán JL: Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study. Circulation 1998;98:112-118.
4. Suzuki J, Tezuka D, Morishita R, Isobe M: An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention. J Gene Med 2009;11:89-91.
5. Welt FG, Rogers C: Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-1776.
6. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A: Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002;90:1167-1172.
7. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
8. Hao H, Gabbiani G, Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 2003;23:1510-1520.
9. Sousa JE, Serruys PW, Costa MA: New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274-2279.
10. Daemen J, Serruys PW: Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 2007;116:316-328.
11. Kraitzer A, Kloog Y, Zilberman M: Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 2008;85:583-603.
12. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
13. Togni M, Räber L, Cocchia R, Wenaweser P, Cook S, Windecker S, Meier B, Hess OM: Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007;120:212-220.
14. Indolfi C, Coppola C, Torella D, Arcucci O, Chiariello M: Gene therapy for restenosis after balloon angioplasty and stenting. Cardiol Rev 1999;7:324-331.
15. Ahn YK, Kook H, Jeong MH, Ahn KY, Cho JG, Park JC, Kang JC, Kim KK: Local RAD50 gene delivery induces regression of preformed porcine coronary in-stent neointimal hyperplasia. J Gene Med 2004;6:93-104.
16. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C; Euroinject One Group: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982-988.
17. Gaffney MM, Hynes SO, Barry F, O'Brien T: Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007;152:175-188.
18. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bächinger H P, Brennan RG, Roberts SG, Green MR, Goodman RH: Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994;370:223-226.
19. Arany Z, Sellers WR, Livingston DM, Eckner R: E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994;77:799-800.
20. Goodman RH, Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-1577.
21. Warner DR, Pisano MM, Greene RM: Functional analysis of CBP/p300 in embryonic orofacial mesenchymal cells. J Cell Biochem 2006;99:1374-1379.
22. Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, Robin P, Knibiehler M, Pritchard LL, Ducommun B, Trouche D, Harel-Bellan A: Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 1998;396:184-186.
23. McManus KJ, Hendzel MJ: CBP, a transcriptional coactivator and acetyltransferase. Biochem Cell Biol 2001;79:253-266.
24. Ghosh S: Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol Res 1999;19:183-189.
25. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG: Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186-34195.
26. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997;89:1175-1184.
27. Matt T: Transcriptional control of the inflammatory response: a role for the CREB-binding protein (CBP). Acta Med Austriaca 2002;29:77-79.
28. Chen J, Jiang H, Xu L, Zhu LH, Wang L, Wen HZ, Hu XR: Dysregulation of CREB binding protein triggers thrombin-induced proliferation of vascular smooth muscle cells. Mol Cell Biochem 2008;315:123-130.
29. Natarajan R, Pei H, Gu JL, Sarma JM, Nadler J: Evidence for 12-lipoxygenase induction in the vessel wall following balloon injury. Cardiovasc Res 1999;41:489-499.
30. Lee YA, Cho EJ, Yokozawa T: Effects of proanthocyanidin preparations on hyperlipidemia and other biomarkers in mouse model of type 2 diabetes. J Agric Food Chem 2008;56:7781-7789.
31. Yang J, Yang J, Ding JW, Chen LH, Wang YL, Li S, Wu H: Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury. Inflammation 2008;31:304-312.
32. Baker AH: Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 2004;84:279-299.
33. Wright MJ, Wightman LM, Lilley C, de Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS, Marber MS: In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001;96:227-236.
34. Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivelä A, Hedman A, Hedman M, Heikura T, Ordén MR, Stacker SA, Achen MG, Hartikainen J, Ylä-Herttuala S: Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109:1029-1035.
35. Bartosch B, Cosset FL: Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther 2004;4:427-443.
36. Costello E, Munoz M, Buetti E, Meylan PR, Diggelmann H, Thali M: Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 2000;7:596-604.
37. Akowuah EF, Gray C, Lawrie A, Sheridan PJ, Su CH, Bettinger T, Brisken AF, Gunn J, Crossman DC, Francis SE, Baker AH, Newman CM: Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Ther 2005;12:1154-1157.
38. West NE, Qian H, Guzik TJ, Black E, Cai S, George SE, Channon KM: Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001;104:1526-1532.
39. Wan S, George SJ, Nicklin SA, Yim AP, Baker AH: Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004;9:689-698.
40. Janknecht R, Wells NJ, Hunter T: TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 1998;12:2114-2119.
41. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG: Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res 2007;17:324-332.
42. Ialenti A, Ianaro A, Maffia P, Carnuccio R, D'Acquisto F, Maiello FM, Di Rosa M: Role of nuclear factor-kappaB in a rat model of vascular injury. Naunyn Schmiedebergs Arch Pharmacol 2001;364:343-350.
43. Jones WK, Brown M, Wilhide M, He S, Ren X: NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor? Cardiovasc Toxicol 2005;5:183-202.
44. Hoberg JE, Popko AE, Ramsey CS, Mayo MW: IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 2006;26:457-471.
45. Saha RN, Jana M, Pahan K: MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 2007;179:7101-7109.